human coagulation factor ii
PolandDrugs containing this active substance
-
The medicinal product is used for the treatment and prevention of bleeding caused by congenital or acquired deficiency of vitamin K-dependent blood clotting factors (II, VII, IX, and X), especially when another appropriate preparation is unavailable.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor ii 200-480 j.m. human coagulation factor vii 100-250 j.m. human coagulation factor ix 200-310 IU human coagulation factor x 220-600 j.m. c protein 150-450 j.m. s protein 130-260 j.m. ATC: B02BD01
Manufacturer: CSL Behring GmbH
-
The medicinal product is used for the treatment and prevention of bleeding caused by congenital or acquired deficiency of vitamin K-dependent blood coagulation factors (II, VII, IX, and X). It is also used to prevent bleeding during surgical procedures.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor x 440-1200 j.m. human coagulation factor vii 200-500 j.m. c protein 300-900 j.m. human coagulation factor ix 400-620 j.m. s protein 260-520 j.m. human coagulation factor ii 400-960 j.m. ATC: B02BD01
Manufacturer: CSL Behring GmbH
-
The medicine is used for the treatment of bleeding, for the prevention of bleeding immediately before and after surgery, and in cases of congenital or acquired deficiency of blood clotting factors.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor ii 480 - 900 IU human coagulation factor vii 500 j.m. human coagulation factor ix 600 j.m. human coagulation factor x 600 j.m. c protein 400 j.m. ATC: B02BD01
Manufacturer: Takeda Manufacturing Austria AG